The Penetration of Misonidazole into a Mature Structural Cartilage

Overview

Journal Br J Cancer

Specialty Oncology

Date 1982 Feb 1

PMID 7059476

Citations 2

Authors

A J Langler

R D Bugden

P Gibson

Affiliations

Soon will be listed here.

Abstract

Mature cartilage may be expected to contain populations of hypoxic cells as a result of the tissues lack of direct vascularization and structure; it may therefore be at risk from possible radiosensitization. The hypoxic-cell radiosensitizing drug misonidazole Ro-07-0582 (MISO) was administered i.v. to mature New Zealand White rabbits at a dose of 100 mg/kg, and the resulting drug concentrations in both blood and ear-cartilage samples measured by HPLC. Samples were taken at regular intervals up to 4 h after administration of MISO. Blood concentrations of MISO rose rapidly to 240 microgram/ml within 5 min of administration, before falling steadily, with a t1/2 of 45 min. Cartilage levels reached a peak of 70% of the blood levels approximately 30 min after administration. The levels of MISO then fell, with a t1/2 of 44 min.

Citing Articles

Distribution and tumor penetration properties of a radiosensitizer 2-[14C] misonidazole (Ro 07-0582), in mice and rats as studied by whole-body autoradiography.

Akel G, Benard P, Canal P, Soula G Cancer Chemother Pharmacol. 1986; 17(2):121-6.

PMID: 3719893 DOI: 10.1007/BF00306739.

Microscopic distribution of misonidazole in mouse tissues.

Cobb L, Nolan J, ONeill P Br J Cancer. 1989; 59(1):12-6.

PMID: 2757919 PMC: 2246964. DOI: 10.1038/bjc.1989.4.

References

Ash D, Smith M, Bugden R . Distribution of misonidazole in human tumours and normal tissues. Br J Cancer. 1979; 39(5):503-9. PMC: 2009904. DOI: 10.1038/bjc.1979.93. View

Stratford I, Adams G . The toxicity of the radiosensitizer misonidazole towards hypoxic cells in vitro: a model for mouse and man. Br J Radiol. 1978; 51(609):745-6. DOI: 10.1259/0007-1285-51-609-745. View

Urtasun R, Band P, Chapman J, Rabin H, Wilson A, Fryer C . Clinical phase I study of the hypoxic cell radiosensitizer RO-07-0582, a 2-nitroimidazole derivative. Radiology. 1977; 122(3):801-4. DOI: 10.1148/122.3.801. View

Wiltshire C, Workman P, Watson J, Bleehen N . Clinical studies with misonidazole. Br J Cancer Suppl. 1978; 3:286-9. PMC: 2149437. View

Silver I . Measurement of pH and ionic composition of pericellular sites. Philos Trans R Soc Lond B Biol Sci. 1975; 271(912):261-72. DOI: 10.1098/rstb.1975.0050. View

White R, Workman P, Freedman L, OWEN L, Bleehen N . The pharmacokinetics of misonidazole in the dog. Eur J Cancer (1965). 1979; 15(10):1233-42. DOI: 10.1016/0014-2964(79)90249-4. View

Gangji D, Poplack D, Schwade J, WOOD J, Strong J . Misonidazole blood and cerebrospinal fluid kinetics in monkeys following intravenous and intrathecal administration. Eur J Cancer (1965). 1981; 17(1):29-34. DOI: 10.1016/0014-2964(81)90208-5. View

McNally N, Denekamp J, SHELDON P, Flockhart I . Hypoxic cell sensitization by misonidazole in vivo and in vitro. Br J Radiol. 1978; 51(604):317-8. DOI: 10.1259/0007-1285-51-604-317. View

Pedersen J, Smith M, Bugden R, Peckham M . Distribution and tumour cytotoxicity of the radiosensitizer misonidazole (Ro-07-0582) in C57 mice. Br J Cancer. 1979; 39(4):429-33. PMC: 2009917. DOI: 10.1038/bjc.1979.76. View

10.

Workman P . Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice. Cancer Chemother Pharmacol. 1980; 5(1):27-37. DOI: 10.1007/BF00578559. View

11.

Flockhart I, Large P, Troup D, Malcolm S, Marten T . Pharmacokinetic and metabolic studies of the hypoxic cell radiosensitizer misonidazole. Xenobiotica. 1978; 8(2):97-105. DOI: 10.3109/00498257809060388. View

12.

Denekamp J, Michael B, Harris S . Hypoxic cell radiosensitizers: comparative tests of some electron affinic compounds using epidermal cell survival in vivo. Radiat Res. 1974; 60(1):119-32. View

13.

Workman P, Little C, Marten T, DALE A, Ruane R, Flockhart I . Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography. J Chromatogr. 1978; 145(3):507-12. DOI: 10.1016/s0378-4347(00)81386-9. View

14.

Churchill-Davidson I, Sanger C, THOMLINSON R . Oxygenation in radiotherapy. II. Clinical application. Br J Radiol. 1957; 30(356):406-22. DOI: 10.1259/0007-1285-30-356-406. View

15.

Dische S, Saunders M, Lee M, Adams G, Flockhart I . Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses. Br J Cancer. 1977; 35(5):567-79. PMC: 2025511. DOI: 10.1038/bjc.1977.90. View

16.

Gray A, Dische S, Adams G, Flockhart I, Foster J . Clinical testing of the radiosensitiser Ro-07-0582. I. Dose tolerance, serum and tumour concentrations. Clin Radiol. 1976; 27(2):151-7. DOI: 10.1016/s0009-9260(76)80137-7. View

17.

McNally N, Denekamp J, Sheldon P, Flockhart I, Stewart F . Radiosensitization by misonidazole (Ro 07-0582). The importance of timing and tumor concentration of sensitizer. Radiat Res. 1978; 73(3):568-80. View

18.

SHELDON P, Hill S . Hypoxic cell radiosensitizers and local control by X-ray of a transplanted tumour in mice. Br J Cancer. 1977; 35(6):795-808. PMC: 2025527. DOI: 10.1038/bjc.1977.121. View

19.

Brown J, Workman P . Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res. 1980; 82(1):171-90. View

20.

Tushan F, Rodnan G, Altman M, Robin E . Anaerobic glycolysis and lactate dehydrogenase (LDH) isoenzymes in articular cartilage. J Lab Clin Med. 1969; 73(4):649-56. View